Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2025-08-24 Investor Presentation
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
投资者关系活动记录表
Investor Presentation Classification · 95% confidence The document is an investor relations activity record from Jiangsu Deyuan Pharmaceutical Co., Ltd. It details a virtual meeting held on August 21-22, 2025, where company executives discussed the company's half-year 2025 operating performance, product development, and other business updates. The document includes specific financial figures for the first half of 2025 and addresses investor questions. However, it is not a full interim or annual report but rather a record of an investor relations event focused on performance discussion and Q&A. This fits best under the category of Investor Presentation (IP), as it is a detailed presentation for investors focusing on financials, strategy, and market position, rather than a formal financial report or announcement.
2025-08-24 Chinese
2025年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "半年度报告摘要" which translates to "Half-Year Report Summary" or "Interim Report Summary" for the year 2025. It contains detailed financial data such as total assets, net profit, earnings per share, and other financial metrics for the reporting period, which is less than a full fiscal year. The document also includes business descriptions, shareholder information, and operational details typical of an interim or quarterly report. The length of the document (7431 characters) and the presence of substantive financial data confirm it is a full report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-18 Chinese
2025年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "半年度报告" which translates to "Half-Year Report" or "Interim Report" for the year 2025. It contains detailed financial data including revenue, profit, assets, liabilities, and operational metrics for the half-year period. It also includes sections on company overview, business operations, risk factors, and financial analysis. The length of the document is substantial (15,000 characters), and it contains actual financial statements and substantive financial data and analysis. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-18 Chinese
第四届监事会第十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the approval of the company's 2025 semi-annual report and its summary. It states that the semi-annual report and summary are published on the Beijing Stock Exchange website with specific announcement numbers. The document itself does not contain the financial data or the report but is a formal meeting resolution approving the report. The document length is short (894 characters) and it references the report being published elsewhere. Therefore, this is an announcement related to the report, not the report itself. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a formal announcement of a meeting resolution and references the report publication but does not contain the report itself or detailed financial data.
2025-08-18 Chinese
第四届董事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the convening and attendance of the fourth board's 13th meeting, including the approval of the 2025 semi-annual report and its summary. The document does not contain the actual semi-annual report or financial data but rather announces the board's approval and references the report being published on the Beijing Stock Exchange website. The document length is short (1011 characters), and it serves as an announcement of a board meeting decision rather than the report itself. Therefore, it fits best under Board/Management Information (MANG) as it relates to board meeting resolutions and decisions.
2025-08-18 Chinese
关于1类新药注射用DYX116新适应症获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the approval of a clinical trial for a new drug injection DYX116 for a new indication. It includes details about the drug, the approval notice from the National Medical Products Administration, and risk warnings related to drug development. The document is short (1181 characters) and serves as a formal notification of regulatory approval rather than a detailed report or financial statement. It does not contain financial data, management discussion, or detailed report content. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-07-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.